Maruho and BMS Partner on Japan Sales for TYK2 Inhibitor Sotyktu
- Maruho and Bristol Myers Squibb (BMS) signed a Japan sales partnership for Sotyktu (deucravacitinib), BMS's oral TYK2 inhibitor, starting October 1, 2026.
- Maruho will handle domestic sales and distribution, promoting the drug in dermatology and rheumatology, while BMS continues promotion in rheumatology.
- Sotyktu is approved for plaque, pustular and erythrodermic psoriasis, with a psoriatic arthritis indication added in May 2026.
💡 Points
BMS ceding Japan commercial lead to Maruho is a tacit admission that dermatologist relationships beat global scale here — the classic foreign-innovator/domestic-specialist access play. Adding rheumatology promotion right after the May PsA nod signals urgency to outrun oral JAK rivals before positioning hardens. For Maruho, it's low-risk topline padding that fits its derm book without R&D exposure.